Skip to main content

Table 4 Total treatment costs for with and without SEB scenarios in year 1

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

Patient type (CKD stage) Treatment for anemia Year 1 total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 28,391,013 24,206,178
Long acting ESA (SC) 29,532,964 25,179,805
Epoetin SEB - 930,614
Stage V Short acting ESA (SC) 23,648,751 20,162,925
Long acting ESA (SC) 16,376,488 13,962,594
Short acting ESA (IV) 97,155,486 82,834,767
Long acting ESA (IV) 67,560,443 57,602,033
Epoetin SEB - 3,193,963
Total 262,665,144 228,045,878
  1. SEB = subsequent entry biologic; CKD = chronic kidney disease; ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.